8/12/19 1 •Chlamydia •Gonorrhea •Trichomoniasis *Syphilis •Herpes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Histopathology and Laboratory Features of Sexually Transmitted Diseases
Histopath & Labs for STIs Endo, Energy and Repro 2017-2018 HISTOPATHOLOGY AND LABORATORY FEATURES OF SEXUALLY TRANSMITTED DISEASES Dominck Cavuoti, D.O. Phone: 469-419-3412 Email: [email protected] LEARNING OBJECTIVES: • Identify the etiologic agents causing pelvic inflammatory disease and the pathologic changes they produce. • Discuss the characteristic clinical and pathologic findings caused by herpes simplex virus (HSV) infections: a. fever blisters b. genital herpes simplex virus infection c. disseminated neonatal HSV • Describe the pathologic changes produced by Treponema pallidum. • Describe the clinical features and pathologic changes produced by Chlamydia trachomatisand Neisseria gonorrhoeae • Describe the clinical and laboratory features of vaginal infections including: Trichomonas, Candida, and bacterial vaginosis. • Describe the clinical and laboratory features of ectoparasite infections PURPOSE OF THE LECTURE: 1. To describe the various agents of sexually transmitted diseases and their disease manifestations 2. To describe the pathologic features associated with STDs 3. To introduce some of the laboratory aspects of STDs TERMS INTRODUCED IN LECTURE: Condyloma lata Disseminated gonococcal infection Gummatous syphilis Lymphogranuloma venereum Pelvic inflammatory disease Rapid Plasma Reagin (RPR) Salpingitis Syphilis/endarteritis obliterans Venereal Disease Research Laboratory (VDRL) Treponema pallidum particle agglutination (TPPA) Histopath & Labs for STIs Endo, Energy and Repro 2017-2018 MAJOR CONCEPTS EMPHASIZED IN LECTURE I. Syphilis (Will be covered by Dr. Norgard in later lecture). II. Gonorrhea A. Causative agent: Neisseria gonorrhoeae, a Gram negative diplococcus. Humans are the only natural reservoir. Infection is acquired via direct contact with the mucosa of an infected person. The incubation period averages 2-5 days with a range of 1-14 days. -
Trichomoniasis — “Trich” for Short — Is an Infection That Is Most Common in Sexually Active Women Age 16 to 35
FACT SHEET FOR PATIENTS AND FAMILIES Trichomoniasis What is trichomoniasis? Trichomoniasis — “trich” for short — is an infection that is most common in sexually active women age 16 to 35. (Men can have trich, too, but usually have fewer symptoms and often don’t need treatment to clear up the infection.) If you have trich, you need medication to stop your symptoms and prevent spreading the infection to sex partners. This handout gives you basic information on trichomoniasis, how it’s treated, and what you can do to prevent it. What causes it? Trichomoniasis is caused by a parasite, a tiny organism called Trichomonas vaginalis. Trich is passed from one person to another through sexual contact. Trich is one of the most common sexually transmitted infections or diseases (STIs or STDs) among young, sexually active women. Recent studies suggest that more Most common in young women, than 2 million women in the U.S. currently have trichomoniasis is a curable infection. trichomoniasis. Why is it a concern? What are the symptoms? Trich is completely curable, but you shouldn’t ignore A woman with trichomoniasis may have one or it. Trich can cause annoying and painful symptoms more of these common symptoms, which may (see the list at right) and may make it easier to catch come and go: another STI such as HIV, the virus that causes AIDS. • Vaginal discharge. The discharge may be gray, If you’re pregnant, trich brings these additional risks: yellow, or green. It may be thin or foamy and may • Your baby may be born too soon smell bad. -
Trichomoniasis Information Handout for Patients
Ottawa County Department of Public Health Family Planning Program Trichomoniasis Information Handout for Patients Trichomoniasis is a sexually transmitted infection caused by the parasite Trichomonas vaginalis. Causes: Trichomoniasis is found worldwide. In the United States, the highest number of cases are seen in women between age 16 and 35. Trichomonas vaginalis is spread through sexual contact with an infected partner. This includes penis-to-vagina intercourse or vulva-to-vulva contact. The parasite cannot survive in the mouth or rectum. The disease can affect both men and women, but the symptoms differ between the two groups. The infection usually does not cause symptoms in men and goes away on its own in a few weeks. Symptoms in Women: •Discomfort with intercourse •Itching of the inner thighs •Vaginal discharge (thin, greenish-yellow, frothy or foamy) •Vaginal itching •Vulvar itching or swelling of the labia •Vaginal odor (foul or strong smell) Symptoms in Men: •Burning after urination or ejaculation •Itching of urethra •Slight discharge from urethra Occasionally, some men with trichomoniasis may develop prostatitis or epididymitis from the infection. Exams and Tests: In women, a pelvic examination shows red blotches on the vaginal wall or cervix. A wet prep (microscopic examination of discharge) may show signs of inflammation or infection-causing organisms in vaginal fluids. A pap smear may also diagnose the condition. The disease can be hard to diagnose in men. Men are treated if the infection is diagnosed in any of their sexual partners. Men may also be treated if they have ongoing symptoms of urethral burning or itching despite treatment for gonorrhea and chlamydia. -
Trichomoniasis Trichomoniasis Is the Most Common Curable Sexually Transmitted Disease (STD) in the United States
Neglected Parasitic Infections in the United States Trichomoniasis Trichomoniasis is the most common curable sexually transmitted disease (STD) in the United States. Trichomoniasis is caused by infection with a parasite (Trichomonas vagi- nalis). Women and men who have trichomoniasis are at higher risk for getting or spreading other STDs, including HIV. About 3.7 million people in the United States are infected with this parasite, and most do not have any signs or symptoms. Trichomoniasis is treated with prescription antimicrobial medication (one dose of metronidazole or tinidazole) but it is possible to become infected again. Trichomoniasis is considered a Neglected Parasitic Infection, one of a group of diseases that can result in serious illness among those who are infected, yet the burden and impact remain poorly understood. How People get Trichomoniasis: Trichomoniasis is a sexually transmitted disease (STD); the parasite is passed from an infected person to an uninfected person during sex. Women and men with trichomoniasis may notice redness, soreness, or itching of the genitals, burning with urination, or discharge. Without treatment, infection can last for months or even years. Some people develop symptoms within 5 to 28 days after being infected, but others do not develop symp- toms until much later or not at all. About 70% of infected people never have any signs or symptoms. Even without any Trichomonas symptoms, infected people can pass the infection to others. Risk Factors for Acquiring Trichomoniasis: • Both men and women can get infected. • People with more sexual partners are more likely to become infected. • Older women may be more likely than younger women to be infected. -
Sexually Transmitted Infections
Disease Awareness April, 2014 • Members Sexually Transmitted Infections Many infections are spread during sex. In this newsletter, we will talk about the 4 most common ones. Human papillomavirus (HPV) Protect yourself What it causes • Learn about sexually transmitted infections Most of the time HPV goes away on its own and doesn’t cause any problems. But many low-risk types of HPV can cause genital warts. High-risk types can • Practice safe sex cause cervical cancer. • Get tested Symptoms Genital warts are a sign of infection with a low-risk type of HPV. The warts can • Get vaccinated to protect against sometimes itch, burn, or feel tender. They can cause bleeding after sex or an HPV and hepatitis B abnormal fluid coming from the vagina. Not all people will have symptoms. There are no symptoms of the high-risk type of HPV. But signs of an infection can be seen on a Pap smear. Testing Testing is not needed to diagnose the low-risk type. But doctors might test these people for infection with a high-risk type. This is because people with genital warts are sometimes infected with both low-risk and high-risk types of HPV. Since there are no symptoms of the high-risk type, it’s very important for women to be screened. Doctors use the Pap test for this and an HPV DNA test that can detect high-risk types. Talk with your doctor about testing if you are 21 years old or older. Treatment HPV that causes genital warts cannot be cured. Medication can be used to help the warts go away. -
Sexually Transmitted Diseases Treatment Options
Sexually transmitted disease (STD) treatment options PREFERRED & ALTERNATIVE OPTIONS Many clinical partners are operating in a limited capacity during the COVID-19 pandemic. Below are preferred (in clinic or other location where injections can be given) and alternative (when only oral medicines are available 1) treatments for STDs. Syndrome Preferred Treatments Alternative Treatments Follow-up Male urethritis syndrome Ceftriaxone 250mg intramuscular (IM) x 1 PLUS Men who have sex with men (MSM) and transgender women2: Patients should be counseled to azithromycin 1g PO x 1 Cefixime 800 mg PO x 1 PLUS doxycycline 100 mg PO BID x 7 days be tested for STDs once clinical Presumptively treating: care is resumed in the local If azithromycin is not available: doxycycline 100 Men who have sex with women only: gonorrhea clinics. Clients who have been mg PO BID for 7 days (except in pregnancy3) Cefixime 800mg PO x 1 PLUS azithromycin 1g PO x 1 referred for oral treatment If cephalosporin allergy5 is reported, gentamicin If cefixime is unavailable, substitute cefpodoxime 400mg PO q12h should return for 240mg IM x 1 PLUS azithromycin 2g PO x 1 x 2 for cefixime in above regimens4 comprehensive testing and screening and linked to services If oral cephalosporin not available or history of cephalosporin at that time. allergy5: azithromycin 2g PO x 1 If azithromycin is not available: doxycycline 100 mg PO BID for 7 days (except in pregnancy3) Patients should be advised to abstain from sex for 7 days Treatment typically guided by examination and For presumptive therapy when examination and laboratory following completion of Vaginal discharge syndrome treatment. -
Genital Dermatology
GENITAL DERMATOLOGY BARRY D. GOLDMAN, M.D. 150 Broadway, Suite 1110 NEW YORK, NY 10038 E-MAIL [email protected] INTRODUCTION Genital dermatology encompasses a wide variety of lesions and skin rashes that affect the genital area. Some are found only on the genitals while other usually occur elsewhere and may take on an atypical appearance on the genitals. The genitals are covered by thin skin that is usually moist, hence the dry scaliness associated with skin rashes on other parts of the body may not be present. In addition, genital skin may be more sensitive to cleansers and medications than elsewhere, emphasizing the necessity of taking a good history. The physical examination often requires a thorough skin evaluation to determine the presence or lack of similar lesions on the body which may aid diagnosis. Discussion of genital dermatology can be divided according to morphology or location. This article divides disease entities according to etiology. The clinician must determine whether a genital eruption is related to a sexually transmitted disease, a dermatoses limited to the genitals, or part of a widespread eruption. SEXUALLY TRANSMITTED INFECTIONS AFFECTING THE GENITAL SKIN Genital warts (condyloma) have become widespread. The human papillomavirus (HPV) which causes genital warts can be found on the genitals in at least 10-15% of the population. One study of college students found a prevalence of 44% using polymerase chain reactions on cervical lavages at some point during their enrollment. Most of these infection spontaneously resolved. Only a minority of patients with HPV develop genital warts. Most genital warts are associated with low risk HPV types 6 and 11 which rarely cause cervical cancer. -
Trichomoniasis (Trich)
health information Trichomoniasis (Trich) Trich is a sexually transmitted infection (STI) caused by a parasite called Trichomonas vaginalis. How do I get trich? Trich is passed between people through unprotected sex (sexual contact without a condom). How can I prevent trich? When you’re sexually active, the best way to prevent trich and other STIs is to use condoms for oral, vaginal, and anal sex. Don’t have any sexual contact if you or your partner(s) have symptoms of an STI, or may have been exposed to an STI. See a doctor or go to an STI Clinic for testing. Get STI testing every 3 to 6 months and when you have symptoms. How do I know if I have trich? The infection is most common in females in the vagina and in males in the tube that carries urine and semen (urethra). Many women with trich have no symptoms, but trich can cause: • vaginal discharge that smells musty • itching in and around the vagina • pain or burning when you pee • pain during intercourse Most males with trich have no symptoms, but they can still spread it. The best way to find out if you have trich is to get tested. Your nurse or doctor can test you by taking a swab. Is trich harmful? If not treated, trich may cause: • infertility or low sperm count in males • increased risk of pelvic infections in females • increased risk of getting other STIs and HIV 608183 © Alberta Health Services, (2014/04) What if I’m pregnant? If not treated, trich may cause premature rupture of the membranes, early delivery, and low birth weight. -
Chlamydia, Gonorrhoea, Trichomoniasis and Syphilis
Research Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016 Jane Rowley,a Stephen Vander Hoorn,b Eline Korenromp,c Nicola Low,d Magnus Unemo,e Laith J Abu- Raddad,f R Matthew Chico,g Alex Smolak,f Lori Newman,h Sami Gottlieb,a Soe Soe Thwin,a Nathalie Brouteta & Melanie M Taylora Objective To generate estimates of the global prevalence and incidence of urogenital infection with chlamydia, gonorrhoea, trichomoniasis and syphilis in women and men, aged 15–49 years, in 2016. Methods For chlamydia, gonorrhoea and trichomoniasis, we systematically searched for studies conducted between 2009 and 2016 reporting prevalence. We also consulted regional experts. To generate estimates, we used Bayesian meta-analysis. For syphilis, we aggregated the national estimates generated by using Spectrum-STI. Findings For chlamydia, gonorrhoea and/or trichomoniasis, 130 studies were eligible. For syphilis, the Spectrum-STI database contained 978 data points for the same period. The 2016 global prevalence estimates in women were: chlamydia 3.8% (95% uncertainty interval, UI: 3.3–4.5); gonorrhoea 0.9% (95% UI: 0.7–1.1); trichomoniasis 5.3% (95% UI:4.0–7.2); and syphilis 0.5% (95% UI: 0.4–0.6). In men prevalence estimates were: chlamydia 2.7% (95% UI: 1.9–3.7); gonorrhoea 0.7% (95% UI: 0.5–1.1); trichomoniasis 0.6% (95% UI: 0.4–0.9); and syphilis 0.5% (95% UI: 0.4–0.6). Total estimated incident cases were 376.4 million: 127.2 million (95% UI: 95.1–165.9 million) chlamydia cases; 86.9 million (95% UI: 58.6–123.4 million) gonorrhoea cases; 156.0 million (95% UI: 103.4–231.2 million) trichomoniasis cases; and 6.3 million (95% UI: 5.5–7.1 million) syphilis cases. -
Sexually Transmitted Diseases Treatment Guidelines, 2015
Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory -
Sexually Transmitted Infections–Summary of CDC Treatment
Sexually Transmitted Infections Summary of CDC Treatment Guidelines—2021 Bacterial Vaginosis • Cervicitis • Chlamydial Infections • Epididymitis Genital Herpes Simplex • Genital Warts (Human Papillomavirus) • Gonococcal Infections Lymphogranuloma Venereum • Nongonococcal Urethritis (NGU) • Pediculosis Pubis Pelvic Inflammatory Disease• Scabies • Syphilis • Trichomoniasis U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention National Network of STD Clinical Prevention Training Centers This pocket guide reflects recommended regimens found in CDC’s Sexually Transmitted Infections Treatment Guidelines, 2021. This summary is intended as a source of clinical guidance. When more than one therapeutic regimen is recommended, the sequence is in alphabetical order unless the choices for therapy are prioritized based on efficacy, cost, or convenience. The recommended regimens should be used primarily; alternative regimens can be considered in instances of substantial drug allergy or other contraindications. An important component of STI treatment is partner management. Providers can arrange for the evaluation and treatment of sex partners either directly or with assistance from state and local health departments. Complete guidelines can be viewed online at https://www.cdc.gov/std/treatment/. This booklet has been reviewed by CDC in July 2021. Accessible version: https://www.cdc.gov/std/treatment-guidelines/default.htm Bacterial Vaginosis Risk Category -
New Medications for BV, Trich, Candida/Yeast, and Herpes
New Medications for BV, Trich, Candida/Yeast, and Herpes New Medications are now available from ITEAMS to treat Bacterial Vaginosis (BV), Trichomoniasis (Trich), Candida/Yeast, Scabies, and Herpes. You can order these medications if you have the ability to test for these infections. Locations who offer only “express visits” (i.e., a blood specimen is collected for HIV and Syphilis and a urine specimen is collected for Gonorrhea and Chlamydia) will not be able to order the new medications. 340B requires providers to have an established relationship with the patient in order to provide medications purchased with 318 funds. A new form must be completed to have these medications added to the list of STD medications you can order through ITEAMS. These medications will be ordered through a new “program” under STD in ITEAMS called “STDT2”. Valacyclovir will be available as: #20 (for Initial HSV Outbreak): 1g po BID x 10 days #5 (for Recurrent HSV Outbreaks: 1g po qd x 5 days Metronidazole will be available as: #4 (for Trichomoniasis): 2 g orally in a single dose #14 (for Bacterial Vaginosis): 500mg BID x 7 days Fluconazole (Brand name Diflucan) #1 (for vulvovaginal yeast infection): 150 mg orally in a single dose 340B requires providers to have an established relationship with the patient in order to provide medications purchased with 318 funds. If you have patients who cannot afford their prescription for the above medications and you are an “express only” clinic, there is an option that is available but it requires some additional steps: 1-Obtain the patient’s consent on agency Release of Information, 2-Request the medical record of the patient as it relates to his/her diagnosis of Herpes, Bacterial Vaginosis, Trichomoniasis, or Candida/Yeast and the medication prescribed.